Evidence map›Paper›PMID 41322194›Full record

ArticleMolecular therapy. Oncology2025

Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models.

Jacob G E Yates, Lily Chan, Alyssa E Bogle, Elena S B Campbell, Arielle N Gillies, Madison E Hughes, Thomas M McAusland, Leonardo Susta, Khalil Karimi, Samuel T Workenhe and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jacob G E YatesDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Lily ChanIntegrative Tumor Immunology and Immunotherapy, Institute Gustave Roussy, 94800 Villejuif, France.
Alyssa E BogleDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Elena S B CampbellDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Arielle N GilliesDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Madison E HughesDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Thomas M McAuslandDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Leonardo SustaDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Khalil KarimiDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Samuel T WorkenheDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Sarah K WoottonDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newcastle disease virus (NDV) exhibits strong immunostimulatory activity and a favorable safety profile, but its moderate monotherapy efficacy may be improved through combination therapies. Although NDV selectively infects and lyses tumor cells, viral infection unintentionally elevates tumor-cell CD47 expression-a "don't-eat-me" signal that could mask the full immunostimulatory potential of NDV. To offset this adverse host response, we engineered NDVs that expressed an anti-CD47 antibody or SIRPα-Fc immunoadhesin to pair direct oncolysis with local CD47 blockade to amplify SIRPα

Indexed as

cancer immunotherapyCD47immune checkpoint blockadeimmune checkpoint inhibitorsMT: Regular IssueNDVoncolytic virus

Identifiers

PMID41322194
PMCPMC12657332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.